SUmmary Current Guideline Subcommittee
The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with hematologic malignancies was developed by the Society for Immunotherapy of Cancer (SITC) and published online by the Journal for ImmunoTherapy of Cancer, in 2016.
This consensus statement provides expert evidence-based recommendations for the use of immunotherapies that include monoclonal antibodies, checkpoint inhibitors, CAR T cells, NK Cells and immunotherapeutic vaccines. This statement includes recommendations for patient selection, toxicity management, clinical end points and sequencing or combination of therapies.
The Cancer Immunotherapy Guidelines Hematologic Malignancies Subcommittee is in the process of addressing updates in the field through the development of three new CIGs: acute leukemia, lymphoma and multiple myeloma. The first of these, the acute leukemia cancer immunotherapy guideline, is now underway.
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia."
Key points from SITC's Cancer Immunotherapy Guidelines have been distilled into Pocket Guides. These condensed, easily accessible versions of the full Cancer Immunotherapy Guidelines are a quick-reference tool available in both digital and print.
Download SITC's Cancer Immunotherapy Pocket Guides on any desktop or mobile device free today.*
*Available only through the Guideline Central App.
ORDER Digital/Print Guides
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org